Argenica Therapeutics (ASX:AGN) Ending Cash Position: A$5.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
25 GF Score
Price A$0.20
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Ending Cash Position?

Argenica Therapeutics ASX:AGN -9.30% 25 Ending Cash Position is A$5.04 Mil as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Argenica Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 was A$5.04 Mil.

Argenica Therapeutics's quarterly Ending Cash Position declined from Dec. 2024 (A$15.08 Mil) to Jun. 2025 (A$10.56 Mil) and declined from Jun. 2025 (A$10.56 Mil) to Dec. 2025 (A$5.04 Mil).

Argenica Therapeutics's annual Ending Cash Position increased from Jun. 2023 (A$9.29 Mil) to Jun. 2024 (A$15.91 Mil) but then declined from Jun. 2024 (A$15.91 Mil) to Jun. 2025 (A$10.56 Mil).

Argenica Therapeutics Ending Cash Position Related Terms

Argenica Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Ending Cash Position Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Ending Cash Position
7.14 8.91 9.29 15.91 10.56

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 8.43 15.91 15.08 10.56 5.04
ASX:AGN
25GF Score
Argenica Therapeutics Ltd ASX:AGN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Argenica Therapeutics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=15.912+-5.357
=10.56

Argenica Therapeutics's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=10.555+-5.518
=5.04

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$5.04 Mil mean?
Argenica Therapeutics (ASX:AGN) has a Ending Cash Position of A$5.04 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Argenica Therapeutics and its competitors.
Is Argenica Therapeutics' Ending Cash Position too high?
Argenica Therapeutics' current Ending Cash Position is A$5.04 Mil. Overall, Argenica Therapeutics has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Ending Cash Position compare to VRTX and REGN?
Argenica Therapeutics' Ending Cash Position of A$5.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Argenica Therapeutics and its competitors. Argenica Therapeutics's current Ending Cash Position is A$5.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Ending Cash Position of A$5.04 Mil. The current Ending Cash Position is A$5.04 Mil. Argenica Therapeutics' overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Ending Cash Position is A$5.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
25GF Score

Get the complete analysis for ASX:AGN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.20
Price